EMD-49361

Single-particle
3.23 Å
EMD-49361
3D View Gallery
Deposition: 21/02/2025
Map released: 08/10/2025
Last modified: 31/12/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-49361
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 9nfb summary report (pdf.gz) Map and 9nfb FULL report (pdf.gz)
EMICSS annotations (xml)

Structure of the cross-HLA supertype antibody R302 bound to a class I MHC presenting a divarasib-modified KRAS-G12C peptide on HLA-A*02

EMD-49361

Single-particle
3.23 Å
EMD-49361
3D View Gallery
Deposition: 21/02/2025
Map released: 08/10/2025
Last modified: 31/12/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Binary complex of Fab R302 with divarasib-conjugated KRAS G12C peptide (5-14) presented by class I MHC having HLA-A*02:01
Fitted models: 9nfb

Deposition Authors: Maso L
Engineered antibodies that stabilize drug-modified KRAS G12C neoantigens enable selective and potent cross-HLA immunotherapy.
Maso L, Mosure SA, Rodriguez-Aponte SA, Pizzo A, Mensah DN, Southard M, Sze S, Ahmed T, Vash B, Hattori T, Rajak E, Koide A, Neel BG, Koide S, Liu W, Toenjes ST, Jardine PDS, Chopra R, Rader C, Stopfer LE
(2025) Nat Commun , 16 , 11264 - 11264
PUBMED: 41408054
DOI: doi:10.1038/s41467-025-66132-w
ISSN: 2041-1723
Grant Support: